MétaCan
Menu
Back to cohort
Record W2622725967 · doi:10.1002/hon.2437_107

COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)

2017· article· en· W2622725967 on OpenAlexaff
Martin Dreyling, Armando Santoro, Luigina Mollica, Sirpa Leppä, George Follows, Georg Lenz, W. Kim, Arnon Nagler, P. Panayiotidis, Judit Demeter, Muhıt Özcan, Marina Kosinova, Krimo Bouabdallah, Franck Morschhauser, Don A. Stevens, David R. Trevarthen, Marius Giurescu, L. Liu, Karl Koechert, Carol E. Peña, Lisa Cupit, Shi Yin, Florian Hiemeyer, J. Garcia‐Vargas, Barrett H. Childs, Pier Luigi Zinzani

Bibliographic record

VenueHematological Oncology · 2017
Typearticle
Languageen
FieldMedicine
TopicChronic Lymphocytic Leukemia Research
Canadian institutionsHôpital Maisonneuve-Rosemont
Fundersnot available
KeywordsMedicineInternal medicineProgressive diseaseGastroenterologyRituximabLymphomaClinical endpointRefractory (planetary science)Phases of clinical researchFollicular lymphomaOncologySurgeryChemotherapyClinical trial

Abstract

fetched live from OpenAlex

Introduction: Treatment options are limited for patients with relapsed/refractory indolent B-cell lymphoma. Copanlisib is an intravenously administered pan-Class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against PI3K-α and PI3K-δ isoforms. We report results from a pivotal phase II study (NCT01660451, part B; CHRONOS 1). Methods: Patients with indolent B-cell non-Hodgkin lymphoma (follicular [FL], marginal zone [MZL], small lymphocytic and lymphoplasmacytoid/Waldenstrӧm macroglobulinemia) and relapsed after, or refractory to, ≥2 prior lines of treatment (including both rituximab and an alkylating agent) were eligible. Copanlisib (60 mg, IV) was intermittently administered on days 1, 8 and 15 of a 28-day cycle. The primary efficacy endpoint was objective tumor response rate (ORR) per independent radiologic review (Cheson et al. 2007). Archival tumor tissues were used for mRNA extraction and gene expression profiling. Results: The full analysis set comprised 142 treated patients. At the time of analysis, median duration of treatment was 22 weeks (range 1-105); 46 patients remained on treatment. The ORR was 59.2%, including 12.0% complete response (CR) and 47.2% partial response (PR), with 29.6% stable disease and 2.1% progressive disease. In the FL subset (n = 104), the ORR was 58.7%, (14.4% CR and 44.2% PR). In the MZL subset (n = 23), the ORR was 69.6%, (8.7% CR and 60.9% PR). Tumor shrinkage as best response was observed in 91% of evaluable patients (Figure). The estimated Kaplan-Meier (KM) median duration of response was 687 days (range 0-687). The KM-estimate of median PFS was 340 days (range 0-736). Gene expression analysis based on evaluable archival samples from 71 patients indicated that high expression of PI3K and B-cell receptor gene signatures was associated with response (p = 0.02 and p = 0.04, respectively). The most common treatment-related AEs (all grade/grade 3+) were transient hyperglycemia (49%/40%) and hypertension (29%/23%). Other AEs included neutropenia (25%/19%), diarrhea (18%/4%), lung infection (14%/11%), pneumonitis (7%/1.4%), and colitis (0.7%/0.7%). There were two non-fatal opportunistic infections. Laboratory toxicities of interest were principally grade-1, including elevated ALT (23% all-grade/19% grade-1) and AST (28%/25%). There were 6 deaths, with 3 attributed to copanlisib: lung infection, respiratory failure, and a thromboembolic event. Keywords: non-Hodgkin lymphoma (NHL); PI3K/AKT/mTOR.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.168
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.342
Teacher spread0.305 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueHematological OncologySame topicChronic Lymphocytic Leukemia ResearchFrench-language works237,207